Skip to content

Clinicalstudy of neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with sub-acuteischemic stroke

Clinicalstudy of neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with sub-acuteischemic stroke

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014497
Enrollment
Unknown
Registered
2018-01-17
Start date
2017-04-01
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sub-acuteischemic stroke

Interventions

Sponsors

148th hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 40~70 years old; complete behavior. They are willing and able to participate in the follow-up test of this study; 2. The symptoms of subacute ischemic stroke caused by ischemia of the internal carotid artery system (the body strength of the paralyzed disease at the level of 0 to III); 3. Three weeks after the onset (plus or minus one week), other nerve function stable; 4. Other lesions were excluded by CT or MRI scan; 5. Non coma patients, check the cooperation; 6. The first or previous history of stroke, but no sequelae; 7. NIHSS (National Institutes of Health Stroke Scale) scale score 4~25 points; 8. To be able to persist in traditional rehabilitation (physical therapy, occupational therapy, or cognitive rehabilitation) for one year.

Exclusion criteria

Exclusion criteria: 1. TIA patients or symptomatic mild or symptomatic rapid improvement, progressive stroke; 2. Fainting; 3. Accept other clinical trials; 4. The blood sugar value 22.2 mmol/l, the blood pressure >150 / 90 mmHg, after medication continue not descend; 5. Heart, lung, liver or kidney failure, due to severe anemia transfusions. Or a confirmed disease, such as a psychosis, is difficult to complete 1 years of research; 6. The patient or its guardian can not or do not want to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Nerve body strength score;National Institutes of Health Stroke Scale;modifled Rankin Scale, MRS;Barthel index;Improved Ashworth spasm scale;Digital pain scale;MRI scans;

Countries

China

Contacts

Public ContactWang Yunliang

148 Hospital of PLA

wangyunliang81@163.com+86 13793308091

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026